Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.

doi:10.1016/j.metabol.2020.154297

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.

Metabolism: clinical and experimental - 1 Sept 2020

Rai Sudhir Kumar, Bril Fernando, Hatch Heather M, Xu Yiling, Shelton Laura, Kalavalapalli Srilaxmi, Click Arielle, Lee Douglas, Beecher Chris, Kirby Austin, Kong Kimi, Trevino Jose, Jha Abhishek, Jatav Shashank, Kriti Kriti, Luthra Soumya, Garrett Timothy J, Guingab-Cagmat Joy, Plant Daniel, Bose Prodip, Cusi Kenneth, Hromas Robert A, Tischler Arthur S, Powers James F, Gupta Priyanka, Bibb James, Beuschlein Felix, Robledo Mercedes, Calsina Bruna, Timmers Henri, Taieb David, Kroiss Matthias, Richter Susan, Langton Katharina, Eisenhofer Graeme, Bergeron Raymond, Pacak Karel, Tevosian Sergei G, Ghayee Hans K

Abstract excerpt

BACKGROUND: Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors that are mostly benign. Metastatic disease does occur in about 10% of cases of PCC and up to 25% of PGL, and for these patients no effective therapies are available. Patients with mutations in the succinate dehydrogenase subunit B (SDHB) gene tend to have metastatic disease. We hypothesized that a down-regulation in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Metabolomics

Share to Mice

Share to Paraganglioma

Share to Pheochromocytoma

Share to Succinate Dehydrogenase

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32562798
DOI: 10.1016/j.metabol.2020.154297
PMCID: PMC7482423

Genes

SDHB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.PMID 32562798Read ↗

Current and Future Therapeutic Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on SDHB TumorsSemantic proximity Read ↗

Loss of SDHB Induces a Metabolic Switch in the hPheo1 Cell Line toward Enhanced OXPHOS.Semantic proximity Read ↗

A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− ratsSemantic proximity Read ↗

Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomasSemantic proximity Read ↗

MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.Semantic proximity Read ↗

Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.Semantic proximity Read ↗

Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.Semantic proximity Read ↗

Targeting polyamine metabolism for cancer therapy and preventionSemantic proximity Read ↗

Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.Semantic proximity Read ↗

A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor ProgressionSemantic proximity Read ↗

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitorsSemantic proximity Read ↗

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.